Application of plasma metabolism-related biomarker detection in the diagnosis of metastatic colorectal cancer
Objective To explore new biomarkers and treatment strategies for patients with non-metastatic colorectal cancer(nmCRC)and metastatic colorectal cancer(mCRC)through targeted metabolomics.Methods A total of 30 nmCRC pa-tients and 30 mCRC patients matched with age and gender were recruited from Shandong Cancer Hospital from 2022-01-01 to 2023-01-01.Plasma samples were collected from patients with nmCRC and mCRC.Plasma metabolites of amino acids,bile acids and fatty acids were measured using liquid chromatography-tandem mass spectrometry,then analyze their corre-lation and diagnostic value.Results A total of 27 amino acids,16 fatty acids and 9 bile acids were detected.Among them,the expression of ethanolamine(P=0.017),taurine(P=0.003),tryptophan(P=0.013),glycocholic acid(P=0.015),C15∶0(P=0.001),C17∶1(P=0.005),C17∶0(P=0.037),C18∶3(P=0.021),C18∶2(P=0.007),C20∶3(P=0.024),C20∶1(P=0.011),C22∶5(P=0.028)and C24∶1(P=0.017)were decreased.Receiver operating characteristic curve(ROC)analysis showed that the area under the curve(AUC)of 13 metabolic markers in the diagnosis of mCRC ranged from 0.668 to 0.809,which could well distinguish nmCRC from mCRC.There was a good correlation between GCA and CA19-9(r=0.736,P=0.036).The mean CA19-9 values of nmCRC and mCRC patients were 25.25± 35.67 and 1 020.56±2 545.23,respectively(t=-2.142,P=0.036).The AUC values of CA19-9 or GCA alone in CRC patients with liver metastases were 0.768 and 0.677,respectively,and the AUC value of CA19-9 combined with GCA was 0.828.Conclusion Metabolomics presents a novel non-invasive identification method for CRC,and is expected to be an effective method for the diagnosis of mCRC.
plasma metabolism-related biomarkerscolorectal cancermetabolomicsliquid chromatography-tandem mass spectrometry
NETL
NSTL
万方数据
